Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study
NACT was more effective in the molecular and dimensional tumor 'downstaging' than NET but baseline molecular features associated with differential responses according to treatment strategy. Examining baseline and post-treatment GE might help tailor more personalized and effective care.
Authors
- Mariavittoria Locci (ORCID: https://orcid.org/0000-0002-3032-583X)
- María Vidal (ORCID: https://orcid.org/0000-0003-1992-5727)
- Francesco Schettini (ORCID: https://orcid.org/0000-0001-6561-1919)
- Tomás Pascual (ORCID: https://orcid.org/0000-0001-8431-3183)
- N. Lorman-Carbó
- Eduard Mensión (ORCID: https://orcid.org/0000-0002-1227-1137)
- Núria Chic (ORCID: https://orcid.org/0000-0001-9736-6276)
- Gabriela Oses (ORCID: https://orcid.org/0000-0001-5843-0909)
- Montserrat Muñoz-Mateu (ORCID: https://orcid.org/0000-0001-7772-1437)
- Aleix Prat (ORCID: https://orcid.org/0000-0003-2377-540X)
- A.B. Rodríguez
- P. Galván
- I. García Fructuoso
- E. Sanfeliu
- S Vidal-Sicart
- F Brasó-Maristany
- M Bergamino
- E Seguí
- R. Gómez Bravo
- O. Martínez-Sáez
- S. Ganau
- B. González-Farre
- B. Adamo
- I Cebrecos
- P. Jares
- M. Mollà
- B. Conte
- S. Nucera
Institutions
- Breast Cancer Research Foundation (US)
- Hospital Clínic de Barcelona (ES)
- Federico II University Hospital (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- University of Naples Federico II (IT)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103989
- Citations
- 17
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Breast Cancer Research Foundation
- AstraZeneca
- Fundación BBVA
- AstraZeneca España
- European Commission
- Fundación Científica Asociación Española Contra el Cáncer
- Daiichi-Sankyo
- Banco Bilbao Vizcaya Argentaria
- European Society for Medical Oncology
- Fundación Fero
- Instituto de Salud Carlos III